Skip to main content
All lobbying filings

Viatris Inc.

Viatris Inc. filed a Q1 report for Viatris Inc. on April 20, 2026.

Lobbying for Viatris Inc.

As filed: VIATRIS INC. for VIATRIS INC.

All filings by Viatris Inc. · Everything Viatris Inc. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$490,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Pennsylvania

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Health Issues

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

Copyright/Patent/Trademark

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S.2296 National Defense Authorization Act

 Bills named in this filing 9
  • S. 891
    Bipartisan Health Care Act
  • H.R. 1843
    To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
  • S. 1302
    Increasing Transparency in Generic Drug Applications Act
  • H.R. 4132
    Prescription Information Modernization Act of 2025
  • S. 2027
    Prescription Information Modernization Act of 2025
  • S. 2658
    Medication Affordability and Patent Integrity Act
  • S. 3778
    Carbon Resource Innovation Act
  • S. 3841
    Last Sale Valuation Act of 2026
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem